The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish

Reviewed 42 sourcesPublished by PepVault

Every GLP-1-family drug in phase 2 or 3 as of November 20, 2026: company, how it works, its key trial and the ClinicalTrials.gov completion date.

Two glasses of water, one with orange and one with mint, a whole orange on a grey napkin, a hand in a blue sleeve
Last reviewed
Sources
42
Questions
9
Compounds
15

The short answer

By our count, 16 drugs built on GLP-1 or its partner hormones are in phase 2 or 3 for weight or liver disease as of November 20, 2026. Per ClinicalTrials.gov, the next big trials to finish their main measurement are retatrutide against tirzepatide (TRIUMPH-5, November 2026, estimated) and Amgen's monthly MariTide (January 21, 2027). CagriSema is closest to approval: Novo expects an FDA decision in Q4 2026.

  • Retatrutide and CagriSema lead: Lilly plans to file retatrutide in Q1 2027, and Novo expects a CagriSema decision in Q4 2026.
  • Three shots given once a month or every four weeks (MariTide, berobenatide and China's zovaglutide) and two new pills, aleniglipron and the zenagamtide tablet, are in phase 3.
  • Amylin on its own (cagrilintide, eloralintide, petrelintide) is the newest class; the first phase 3 trial of it, cagrilintide's RENEW 1, reaches primary completion in May 2027 (estimated).
  • A primary completion date is when the last measurement is taken, not when results come out.

Every number checked at its primary source · · 42 sources · How we research

Evidence: Registry records and phase 2 and 3 trial results. None of the 16 drugs in the main table is approved by the FDA as of November 20, 2026 (mazdutide is approved in China); dates marked estimated are the registry's and can move.

Two glasses of water, one with orange and one with mint, a whole orange on a grey napkin, a hand in a blue sleeve

Which GLP-1 drugs are in phase 2 and 3 right now?

By our count, the table holds every drug in the GLP-1 family with a phase 2 or 3 weight or liver trial on ClinicalTrials.gov, as of November 20, 2026. Each row names one key trial: the one that finishes next, or the main weight trial. Primary completion is the registry's own date for the last participant's main measurement; an "estimated" date can move. A phase 3 trial is the large, final test before a company files for approval (glossary: /glossary/clinical-trial-phases).

DrugCompanyHow it worksPhaseKey trialPrimary completion, per ClinicalTrials.govOur page
RetatrutideEli LillyWeekly shot on the GIP, GLP-1 and glucagon receptors (a triple agonist)2Phase 3; Lilly plans to file in Q1 20273TRIUMPH-5, against tirzepatide, NCT066623831November 2026 (estimated)/peptides/retatrutide
CagriSemaNovo NordiskWeekly shot: the amylin analogue cagrilintide plus semaglutide6Filed December 2025; Novo expects an FDA decision in Q4 20265NCT07011667, 609 adults7March 1, 2027 (estimated)/peptides/cagrisema
Cagrilintide aloneNovo NordiskWeekly long-acting amylin analogue, the fullness hormone9Phase 3RENEW 1, NCT072206428May 11, 2027 (estimated)/peptides/cagrilintide
MariTide (maridebart cafraglutide)AmgenMonthly shot: an antibody that blocks the GIP receptor, joined to GLP-1 agonist peptides4Phase 3MARITIME-1, NCT0685883910January 21, 2027 (estimated)/peptides/maritide
Berobenatide (PF-08653944, MET-097)PfizerUltra-long-acting GLP-1 analogue, tested weekly and monthly11Phase 3VESPER-4, weekly, NCT0731185012September 21, 2027 (estimated)None yet
Zenagamtide (amycretin)Novo NordiskOne molecule on the GLP-1, amylin and calcitonin receptors, as a shot and a pill13Phase 3AMAZE 1, NCT0733942314June 26, 2029 (estimated)/peptides/amycretin
AleniglipronStructure Therapeutics (trials under its subsidiary Gasherbrum Bio)Daily pill: a small chemical molecule that works the GLP-1 receptor15Phase 3ACCOMPLISH-1, NCT0765436116September 2028 (estimated)None yet
SurvodutideBoehringer IngelheimWeekly shot on the glucagon and GLP-1 receptors17Phase 3; SYNCHRONIZE-1 and -2 finished, more weight and liver trials running18SYNCHRONIZE-1, NCT06066515 (main weight trial)18December 2, 2025 (actual)/peptides/survodutide
VK2735Viking TherapeuticsWeekly shot on the GLP-1 and GIP receptors; a pill version is in phase 3 too19Phase 3VANQUISH 1, NCT0710450020July 1, 2027 (estimated)/peptides/vk2735
EloralintideEli LillyWeekly shot on the amylin receptor alone21Phase 3ENLIGHTEN-1, NCT0732188622March 2028 (estimated)/peptides/eloralintide
PetrelintideRoche (from Zealand Pharma)Weekly long-acting amylin analogue23Phase 3ZUPREME-3, NCT0784349824December 21, 2028 (estimated)/peptides/petrelintide
MazdutideInnovent BiologicsWeekly shot on the GLP-1 and glucagon receptors25Approved in China for weight since June 2025; phase 3 in fatty liver41GLORY-3, against semaglutide in fatty liver, China, NCT0688429326December 31, 2026 (estimated)/peptides/mazdutide
PemvidutideAltimmuneWeekly shot on the glucagon and GLP-1 receptors, tested for MASH, the inflamed fatty liver27Phase 3PERFORMA, NCT0779516428December 2028 (estimated)/peptides/pemvidutide
Ribupatide (HRS9531)Fujian Shengdi PharmaceuticalWeekly shot on the GLP-1 and GIP receptors29Phase 3, ChinaAgainst semaglutide, NCT0728590230March 2027 (estimated)None yet
ZovaglutideBeijing QL BiopharmaceuticalA shot every four weeks; the registry does not name its target31Phase 3, ChinaHORIZON-1, NCT0723011931May 29, 2027 (estimated)None yet
OlatorepatideRegeneron (licensed from Hansoh Pharma, which calls it HS-20094)A shot on the GLP-1 and GIP receptors42Phase 2; phase 3 RISE-1 not yet recruiting33NCT07431086, 120 adults32November 13, 2026 (estimated; the date has passed and no result is posted)None yet

If one of these drugs reaches you, through a trial or a prescription, PepVault logs each dose, your side effects and your weight, and builds a report you can bring to your prescriber. Log it in PepVault

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

If one of these drugs reaches you, through a trial or a prescription, PepVault logs each dose, your side effects and your weight, and builds a report you can bring to your prescriber.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What reads out next, in date order?

These are the registry's primary completion dates for the next six months (estimates, and they can move), plus the two meetings where obesity data usually appears. A primary completion is the last main measurement, not a result: results tend to follow by weeks to months, often as a company press release first.

Date (primary completion unless a meeting)WhatDrug
November 2026TRIUMPH-5, about 800 adults, against tirzepatide1Retatrutide
November 13, 2026 (passed, no result posted)Phase 2, 120 adults32Olatorepatide
December 31, 2026GLORY-3, phase 3 against semaglutide in fatty liver, China26Mazdutide
January 21, 2027MARITIME-1 (3,853 adults) and MARITIME-2 (1,105, with type 2 diabetes)10MariTide
March 1, 2027Phase 3 weight trial, 609 adults7CagriSema
March 2027Phase 3 against semaglutide, 572 adults30Ribupatide
May 11, 2027RENEW 1, 300 adults8Cagrilintide alone
May 18 to 21, 2027European Congress on Obesity, Munich34Many
June 18 to 21, 2027American Diabetes Association Scientific Sessions, Washington, D.C.35Many

Is retatrutide better than tirzepatide?

That is the question TRIUMPH-5 answers, and it is the pipeline's next big moment. Retatrutide's main phase 3 weight trial, TRIUMPH-1, set the bar: 25.0% average weight loss on 12 mg at 80 weeks, against 3.9% on placebo, counting everyone who started2. The head-to-head's design and the numbers it has to beat are in our guide TRIUMPH-5 results (/guides/triumph-5-results); the filing and the FDA clock are in When will retatrutide be approved? (/guides/when-will-retatrutide-be-approved).

When will CagriSema be approved?

CagriSema is the pipeline drug nearest the pharmacy. Novo filed it with the FDA in December 2025 for 2.4 mg of each drug and, on November 14, 2026, still expected a decision in Q4 2026; it is not approved in the US5. In REDEFINE 1, weight fell 20.4% at 68 weeks, against 3.0% on placebo6. The decision, the doses and the label to expect are in CagriSema FDA approval (/guides/cagrisema-fda-decision); what amylin adds is in Cagrilintide and CagriSema (/guides/cagrilintide-and-cagrisema); and the side-by-side with Zepbound and Wegovy is in its own guide (/guides/cagrisema-vs-zepbound-vs-wegovy).

Is there a monthly GLP-1 shot coming?

Three are in phase 3. MariTide works differently from every approved drug: it switches the GLP-1 receptor on and blocks the GIP receptor, and in phase 2 weight fell 12.3% to 16.2% at 52 weeks, against 2.5% on placebo4. Pfizer's berobenatide runs phase 3 trials both weekly and monthly12, and Beijing QL's zovaglutide, a shot every four weeks, is in phase 3 in China31. MariTide and berobenatide are compared in Is there a monthly GLP-1 shot? (/guides/monthly-glp-1-shots), berobenatide has its own guide (/guides/berobenatide-explained), and the bar MARITIME-1 must clear is in MariTide phase 3 results (/guides/maritime-1-results).

Which GLP-1 pills are coming?

Aleniglipron is a once-daily pill made of a small chemical molecule rather than a peptide; in its phase 2b trial, weight fell up to 11.3% more than on placebo at 36 weeks15. Novo's zenagamtide is in phase 3 as a daily tablet as well as a weekly shot13. Aleniglipron and its trial switching people from shots to the pill are in our aleniglipron guide (/guides/aleniglipron-switch-trial). Two pills have already left the pipeline, covered below.

What does amylin add, and who is testing it?

Amylin is a fullness hormone the pancreas releases with insulin, and it is the pipeline's newest class9. Three companies test it alone: Novo's cagrilintide, Lilly's eloralintide and Roche's petrelintide. Eloralintide alone cut weight by up to 20% at 48 weeks in phase 2, against 0.4% on placebo, among people who stayed on treatment21. Petrelintide cut 7.9% to 9.8% at 28 weeks, against 1.7% on placebo, also among people on treatment23. The first phase 3 trial of amylin alone to finish is cagrilintide's RENEW 1, with primary completion estimated for May 11, 20278. All three, with zenagamtide, are side by side in The amylin drugs in trials (/guides/amylin-drugs-in-trials).

Which drugs already left the pipeline?

  • The Wegovy pill (semaglutide tablets), FDA approved December 22, 202536. Our guide: The Wegovy pill (/guides/the-wegovy-pill).
  • Foundayo (orforglipron), Lilly's daily pill, FDA approved April 1, 202637. In its main trial, weight fell 11.2% at the top trial dose at 72 weeks, against 2.1% on placebo38. Lilly is still running phase 3 trials in other groups, such as people with type 2 diabetes (NCT06972472, primary completion August 2027)39. Our guide: Foundayo vs the shots (/guides/foundayo-vs-the-shots).
  • Ecnoglutide (Sciwind), approved in China for weight in March 2026; it is not approved in the US40.

Mazdutide is approved in China too, but stays in the table above for its phase 3 liver trial41. The approved brands, side by side, are on our drugs page (/drugs). Regeneron's olatorepatide, the newest name in the table, has its own guide (/guides/olatorepatide-explained).

How do you check a trial date yourself?

Dates in this table move, so here is how to read one at the source. It takes about a minute.

  1. Open clinicaltrials.gov/study/ followed by the trial's NCT number, for example clinicaltrials.gov/study/NCT06662383.
  2. Read the sponsor under "Sponsor": it should be the company that owns the drug or its named subsidiary. A sponsor you cannot match to the drug's owner is a reason to doubt the record.
  3. Find "Primary Completion" in the study details, and note whether it says "Estimated" or "Actual".
  4. Check "Last Update Posted": an estimate updated last month is worth more than one untouched for a year.
  5. Look for a "Results posted" tab. Do not expect it on the day: results usually come first as a company press release or a conference talk, and reach the registry later.

If you are in one of these trials, PepVault can keep your own record next to it: each dose as you logged it, your weekly weigh-ins and the side effects you noted. Track your weight in PepVault

Track it in the app

Sources

  1. ClinicalTrials.gov NCT06662383 (TRIUMPH-5), Eli Lilly; read at the v2 API Nov 20, 2026 clinicaltrials.gov
  2. Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. 2026;395:1781-1793. PubMed 42814954
  3. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3); plans to submit in Q1 2027. Press release, July 23, 2026. prnewswire.com
  4. Jastreboff AM et al. Once-monthly maridebart cafraglutide for the treatment of obesity: a phase 2 trial. N Engl J Med. 2025. PubMed 40549887
  5. Novo Nordisk. CagriSema demonstrated approx. 21% average weight loss (REDEFINE 9). Company announcement, Nov 14, 2026. novonordisk.com
  6. Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025;393:635-647. PubMed 40544433
  7. ClinicalTrials.gov NCT07011667 (CagriSema, 609 adults), Novo Nordisk clinicaltrials.gov
  8. ClinicalTrials.gov NCT07220642 (RENEW 1, cagrilintide), Novo Nordisk clinicaltrials.gov
  9. Lau DCW et al. Once-weekly cagrilintide for weight management: a phase 2 trial. Lancet. 2021. PubMed 34798060
  10. ClinicalTrials.gov NCT06858839 (MARITIME-1) and NCT06858878 (MARITIME-2), Amgen clinicaltrials.gov
  11. ClinicalTrials.gov NCT06712836 (VESPER-1, MET097), Pfizer: intervention description clinicaltrials.gov
  12. ClinicalTrials.gov NCT07311850 (VESPER-4, weekly), Pfizer; also NCT07595549 (VESPER-6, once-monthly PF-08653944) clinicaltrials.gov
  13. Mora et al. Once-weekly subcutaneous zenagamtide in type 2 diabetes: a phase 2 trial. Lancet. 2026; and AMAZE 9 (NCT07720271, zenagamtide tablets). PubMed 42532080
  14. ClinicalTrials.gov NCT07339423 (AMAZE 1), Novo Nordisk clinicaltrials.gov
  15. Rosenstock J et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a phase 2b trial. Nat Med. 2026. PubMed 42249138
  16. ClinicalTrials.gov NCT07654361 (ACCOMPLISH-1), Gasherbrum Bio, a wholly owned subsidiary of Structure Therapeutics clinicaltrials.gov
  17. Wharton S et al. Survodutide once weekly in adults with obesity and type 2 diabetes (SYNCHRONIZE-2). N Engl J Med. 2026. PubMed 42820639
  18. ClinicalTrials.gov NCT06066515 (SYNCHRONIZE-1) and NCT06066528 (SYNCHRONIZE-2), both completed; running phase 3: NCT07850050, NCT07855900 (weight), NCT06632457 (MASH cirrhosis); Boehringer Ingelheim clinicaltrials.gov
  19. Bays H et al. Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist: phase 2 VENTURE study. Obesity. 2026; and SUNRISE 1 (NCT07868835, oral VK2735). PubMed 41508550
  20. ClinicalTrials.gov NCT07104500 (VANQUISH 1), Viking Therapeutics clinicaltrials.gov
  21. Billings LK et al. Eloralintide, a selective amylin receptor agonist: a 48-week phase 2 trial. Lancet. 2025. PubMed 41207310
  22. ClinicalTrials.gov NCT07321886 (ENLIGHTEN-1), Eli Lilly clinicaltrials.gov
  23. Garvey WT et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a phase 2 trial. Lancet Diabetes Endocrinol. 2026. PubMed 42810355
  24. ClinicalTrials.gov NCT07843498 (ZUPREME-3), Hoffmann-La Roche clinicaltrials.gov
  25. Ji L et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1). N Engl J Med. 2025. PubMed 40421736
  26. ClinicalTrials.gov NCT06884293 (IBI362 vs semaglutide), Innovent Biologics clinicaltrials.gov
  27. Noureddin M et al. Weekly pemvidutide versus placebo for MASH (IMPACT): 48-week results. Lancet Gastroenterol Hepatol. 2026. PubMed 43014327
  28. ClinicalTrials.gov NCT07795164 (PERFORMA), Altimmune clinicaltrials.gov
  29. He et al. Preclinical and first-in-human evaluation of ribupatide (HRS9531), a dual GLP-1/GIP receptor agonist. Diabetes Obes Metab. 2026. PubMed 42764407
  30. ClinicalTrials.gov NCT07285902 (HRS9531 vs semaglutide), Fujian Shengdi Pharmaceutical clinicaltrials.gov
  31. ClinicalTrials.gov NCT07230119 (zovaglutide, HORIZON-1), Beijing QL Biopharmaceutical clinicaltrials.gov
  32. ClinicalTrials.gov NCT07431086 (olatorepatide phase 2), Regeneron clinicaltrials.gov
  33. ClinicalTrials.gov NCT07896265 (RISE-1, olatorepatide phase 3), Regeneron clinicaltrials.gov
  34. European Congress on Obesity 2027, Munich, 18-21 May 2027 (congress site) eco2027.org
  35. American Diabetes Association. Scientific Sessions, June 18-21, 2027, Washington, D.C. professional.diabetes.org
  36. Drugs@FDA. NDA 218316, Wegovy (semaglutide) tablets: original approval Dec 22, 2025. accessdata.fda.gov
  37. Drugs@FDA. NDA 220934, Foundayo (orforglipron): original approval Apr 1, 2026. accessdata.fda.gov
  38. Wharton S et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025. PubMed 40960239
  39. ClinicalTrials.gov NCT06972472 (orforglipron in obesity and type 2 diabetes), Eli Lilly clinicaltrials.gov
  40. Shirley M. Ecnoglutide: first approvals. Drugs. 2026. PubMed 42412371
  41. Shirley M. Mazdutide: first approval. Drugs. 2025;85:1621-1627. PubMed 41028652
  42. Hansoh Pharma. Hansoh Pharma grants Regeneron an exclusive license to its investigational dual GLP-1/GIP receptor agonist HS-20094. Press release, June 2, 2025. hansoh.cn

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo